Generation of V α13/β21+T cell specific target CML cells by TCR gene transfer

// Xianfeng Zha 1, 2, 3 , Ling Xu 2 , Shaohua Chen 2 , Lijian Yang 2 , Yikai Zhang 2 , Yuhong Lu 4 , Zhi Yu 4 , Bo Li 2 , Xiuli Wu 2 , Wenjie Zheng 3 , Yangqiu Li 2, 4, 5 1 Department of Clinical Laboratory, First Affiliated Hospital, Jinan University, Guangzhou, China 2 Institute of Hematology, Jinan University, Guangzhou, China 3 Department of Chemistry, Jinan University, Guangzhou, China 4 Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China 5 Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China Correspondence to: Yangqiu Li, email: yangqiuli@hotmail.com Keywords: chronic myeloid leukemia, T cell receptor, gene transfer, immunotherapy Received: May 02, 2016      Accepted: September 13, 2016      Published: October 04, 2016 ABSTRACT Adoptive immunotherapy with antigen-specific T cells can be effective for treating melanoma and chronic myeloid leukemia (CML). However, to obtain sufficient antigen-specific T cells for treatment, the T cells have to be cultured for several weeks in vitro , but in vitro T cell expansion is difficult to control. Alternatively, the transfer of T cell receptors (TCRs) with defined antigen specificity into recipient T cells may be a simple solution for generating antigen-specific T cells. The objective of this study was to identify CML-associated, antigen-specific TCR genes and generate CML-associated, antigen-specific T cells with T cell receptor (TCR) gene transfer. Our previous study has screened an oligoclonal Vβ21 with a different oligoclonal Vα partner in peripheral blood mononuclear cells (PBMCs) derived from patients with CML. In this study, oligoclonally expanded TCR α genes, which pair with TCR Vβ21, were cloned into the pIRES eukaryotic expression vector (TCR Vα-IRES-Vβ21). Next, two recombinant plasmids, TCR Vα13-IRES-Vβ21 and TCR Vα18-IRES-Vβ21, were successfully transferred into T cells, and the TCR gene-modified T cells acquired CML-specific cytotoxicity with the best cytotoxic effects for HLA-A11 + K562 cells observed for the TCR Vα13/Vβ21 gene redirected T cells. In summary, our data confirmed TCRVα13/Vβ21 as a CML-associated, antigen-specific TCR. This study provided new evidence that genetically engineered antigen-specific TCR may become a druggable approach for gene therapy of CML.